Poolbeg Pharma A Strategic Vision, Pioneering the Future of Innovative Medicine

Poolbeg Pharma Plc (LON:POLB) Investor Presentation for January 2024 presented by CEO Jeremy Skillington and outlines the company’s strategic shift towards generating sustainable revenue and achieving profitability.

It highlights Poolbeg’s focus on the development and commercialisation of innovative medicines for unmet medical needs. Key components include the leveraging of a proven leadership team with a successful track record in the pharmaceutical industry, a business model centred around revenue generation from commercial-stage products, and the development of high-value programs for partnering, including their lead candidate POLB 001 for cancer immunotherapy-induced CRS and severe influenza. The presentation also discusses the company’s strong financial position and ongoing strategic collaborations.

Click to view all articles for the EPIC:
Or click to view the full company profile:

More articles like this

POLB 001: Targeting CRS in Cancer Immunotherapy

Phase 2 Ready orally administered p38 MAP Kinase inhibitor – a preventative therapy targeting an addressable market of more than $10 billion. POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer

Poolbeg Pharma updates on Immunomodulator II Patent

Poolbeg Pharma has announced that it has received a Notice of Allowance from the US Patent Office in relation to its Immunomodulator II patent application. A Notice of Allowance is a precursor to the expected formal grant

February hires in Pharma

February may be the shortest month, but we got an extra day this year and that left plenty of time for personnel announcements in the pharma world. Read on for a roundup of the month’s hiring

Poolbeg Pharma’s Cathal Friel assumes role of Executive Chairman

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced a change of Board role and the Remuneration Committee’s approval of

What will cancer therapy look like in 2034?

Drugs like PARP inhibitors and chimeric antigen receptor (CAR) therapies, and advancements in artificial intelligence in drug discovery, have spurred hope for improved cancer care in the past year. Rigorous research has paved the way for a